ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17 juin 2022 07h00 HE
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17 juin 2022 01h00 HE
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
25 mai 2022 07h00 HE
|
ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
25 mai 2022 01h00 HE
|
ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09 mai 2022 07h00 HE
|
ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09 mai 2022 01h00 HE
|
ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...
The Fibroid Foundation Announces Fibroid Summit 2022 - a Patient-Hosted Research Conference
01 févr. 2022 10h30 HE
|
The Fibroid Foundation
WASHINGTON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- The Fibroid Foundation in collaboration with The Campion Fund will host The Fibroid Summit, featuring leading researchers on Feb. 8 and 9, 2022. The...
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17 déc. 2021 07h00 HE
|
ObsEva SA
-European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration- Ad hoc...
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17 déc. 2021 01h00 HE
|
ObsEva SA
-European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration- Ad hoc...
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
22 nov. 2021 01h05 HE
|
ObsEva SA
FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA,...